Abstract
Purpose
To evaluate the geographic pattern of central retinal sensitivity and its resolution shortly after intravitreal injection of triamcinolone acetonide (IVTA) for diabetic macular edema (DME).
Methods
Twenty eyes of 20 patients who underwent IVTA for the treatment of DME were reviewed retrospectively. Early changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), photoreceptor inner and outer segments (IS/OS) line and central retinal sensitivity were analyzed. Retinal sensitivity was measured at 40 points within the central 10 degrees of the macula with the Micro Perimeter 1 before treatment, and at 1 week and 1 month after IVTA.
Results
Mean BCVA and CMT improved significantly at 1 week and 1 month after IVTA. Mean retinal sensitivity, however, showed no significant improvement at 1 week (P = 0.238), but did show significant improvement at 1 month (P = 0.0003). Mean retinal sensitivity of the points at the central 2 degrees, which was significantly lower than that at 6 and 10 degrees before treatment, showed improvement similar to those of 6 and 10 degrees after IVTA. Mean retinal sensitivity in the nasal quadrant of the macular area had the best sensitivity at all time points, and improved more than it did in the other quadrants. Mean retinal sensitivity in the central 2 degrees was better in the eyes with complete IS/OS line (P < 0.0001).
Conclusions
BCVA and CMT improved significantly after IVTA for DME. Retinal sensitivity also showed significant, albeit relatively slow, improvement. The nasal quadrant of the macular area showed more improvement than did any other quadrant.
Similar content being viewed by others
References
Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94:761–774
Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29:2–6
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772
Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, Gangnon RE, Puliafito CA (2004) Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 122:1131–1136
Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN (2004) Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 122:1137–1140
Jonas JB, Kreissig I, Degenring RF (2003) Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136:384–386
Conway MD, Canakis C, Livir-Rallatos C, Peyman GA (2003) Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29:27–33
Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A (2003) Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 135:246–249
Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533–1538
Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044–2049
Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S (2004) Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 88:1131–1136
Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927
Bardak Y, Cekic O, Sahin Tig U, Bardak H (2007) Alterations in central retinal sensitivity after intravitreal triamcinolone injection for diffuse diabetic macular edema. Eur J Ophthalmol 17:780–784
Grenga P, Lupo S, Domanico D, Vingolo EM (2008) Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study. Retina 28:1270–1275
Karacorlu M, Ozdemir H, Senturk F, Arf Karacorlu S, Uysal O (2008) Macular function by multifocal electroretinogram in diabetic macular edema after intravitreal triamcinolone acetonide injection. Eur J Ophthalmol 18:601–608
Ozkiris A, Evereklioglu C, Oner A, Erkilic K (2004) Pattern electroretinogram for monitoring the efficacy of intravitreal triamcinolone injection in diabetic macular edema. Doc Ophthalmol 109:139–145
Jonas JB, Sofker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427
Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61
Diabetic Retinopathy Clinical Research Network (DRCR.net) (2009) Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245–251
Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B (2005) Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol 140:295–301
Uckermann O, Kutzera F, Wolf A, Pannicke T, Reichenbach A, Wiedemann P, Wolf S, Bringmann A (2005) The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther 315:1036–1045
Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC (2008) Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57:1026–1033
Wolf S, Arend O, Schulte K, Ittel TH, Reim M (1994) Quantification of retinal capillary density and flow velocity in patients with essential hypertension. Hypertension 23:464–467
Unoki N, Nishijima K, Sakamoto A, Kita M, Watanabe D, Hangai M, Kimura T, Kawagoe N, Ohta M, Yoshimura N (2007) Retinal sensitivity loss and structural disturbance in areas of capillary nonperfusion of eyes with diabetic retinopathy. Am J Ophthalmol 144:755–760
Acknowledgment
This study was supported in part by Grants-in-aid for Scientific Research No. 19592016 from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan.
Author information
Authors and Affiliations
Corresponding author
Additional information
No conflict of interest or commercial or proprietary interests exist for any of the authors. The authors have full control of all primary data, and agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Rights and permissions
About this article
Cite this article
Kameda, T., Nishijima, K., Unoki, N. et al. Geographic pattern of central retinal sensitivity after intravitreal triamcinolone for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 249, 3–9 (2011). https://doi.org/10.1007/s00417-010-1447-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-010-1447-1